Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis

Elias S. Sotirchos; Pavan Bhargava; Christopher Eckstein; Keith Van Haren; Moira Baynes; Achilles Ntranos; Anne Gocke; Lawrence Steinman; Ellen M. Mowry; Peter A. Calabresi

doi:10.1212/WNL.0000000000002316

Full PDF

Citation

Permissions

Comment

Downloads

1367

AAN Members: Sign in with your AAN member credentials (e-mail or 6-digit Member ID number)

Non-AAN Member subscribers: Sign in with subscriber credentials

Purchase access

AAN members must change their passwords on the AAN site

For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)

Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here

Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00.

Disputes & Debates: Rapid online correspondence

Author response to Drs. Golan & Miller
Elias S. Sotirchos

Published May 11, 2016
Re:Vitamin-D supplementation: Is the MS community studying too high a dose?
Elias S. Sotirchos

Published April 26, 2016
Vitamin-D supplementation: Is the MS community studying too high a dose?
Daniel Kantor

Published April 12, 2016
The influence of Vitamin D supplementation on Th-17 cell activity in patients with Multiple Sclerosis
Daniel Golan

Published February 25, 2016
Re: Vitamin D and MS: Not all is hunky dory
Elias S. Sotirchos

Published February 22, 2016
Vitamin D and MS: Not all is hunky dory
Jagannadha Avasarala

Published February 04, 2016

Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

Stay timely. Submit only on articles published within the last 8 weeks.
Do not be redundant. Read any comments already posted on the article prior to submission.
200 words maximum.
5 references maximum. Reference 1 must be the article on which you are commenting.
5 authors maximum. Exception: replies can include all original authors of the article.
Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose comment

Title *

Author Information

NOTE: The first author must also be the corresponding author of the comment.

Contributors
First Name and Middle Initial * First or given name, e.g. 'Peter'. Last Name * Your last, or family, name, e.g. 'MacMoody'. Email Address * Your email address, e.g. higgs-boson@gmail.com Occupation * Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation * Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Publishing Agreement

I, the first and corresponding author, verify that I have read the contents of the PUBLISHING AGREEMENT form. *

I, the first and corresponding author, verify my disclosures and those of my co-authors are up to date at http://submit.neurology.org. *

Select only one of the three options below: *

I am an Author of this Work, and the Work was prepared on my own time - not as part of my duties as an employee.

I prepared (or cooperated in the preparation of) the Work as part of my duties as an employee, and the Work is, therefore, a "work made for hire", as defined by the United States Copyright Act of 1976, as amended.

I prepared (or participated in the preparation of) the Work as part of my official duties as an officer or employee of the United States Government.

NOTE: All contributors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.

Competing interests? *

Yes

Please describe the competing interests

Main menu

User menu

Search

Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis

Citation Manager Formats

Purchase access

Disputes & Debates: Rapid online correspondence

Plain text

Vertical Tabs

You May Also be Interested in

More Online

Topics Discussed

Alert Me

Articles

About

Submit

Subscribers

Main menu

User menu

Search

Share

Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis

Citation Manager Formats

Share

Log in using your username and password

Purchase access

Disputes & Debates: Rapid online correspondence

Plain text

Vertical Tabs

You May Also be Interested in

More Online

Related Articles

Topics Discussed

Alert Me

Articles

About

Submit

Subscribers